Global Car T Cell Therapy Market Outlook and Car T Cell Therapy Clinical Trials Insight 2022

The research in immunotherapy has unlocked the way to harness an individual’s immune response to fight against the tumors and cancers. Many of the ideas have tried to make the use of natural killer cells or B cell, however, the research has not moved a past conceptual thinking. Immuno-oncology is an evolving treatment modality with the agents which being studied for their potential to provide the long term survival across a broad range of tumor types.

The idea of targeting the immune system as a therapeutic approach in cancer is not new. Cytokines have been used for decades, predominantly in patients with renal cell carcinoma and melanoma. However, the cytokines is not the target specific and have been associated with the significant toxicity and limited the efficacy. These limitations restrict the patients to use this method.

The experience of using the T cells which includes the engineering of T cells with the expressing chimeric antigen specific receptors, are providing the proof of concept data for an emerging area of cellular therapy. Biopharma is taking the steps to personalize the cancer care by the use of CAR T cells. Immuno-oncology and the cell therapies will change the face of cancer care especially in solid tumors and high risk malignancies.

The clinical successes with CD-19 CAR T cells in leukemia and lymphoma have boosted the field and led to significant pharmaceutical venture capital funding. Despite the great success in CAR T cell therapies, several challenges are still need to address. The first is the extension of CAR T cell therapy across the 2 different arenas of diseases and institutions. Although the target identification is an area of active investigation, promising targets remain indefinable for many diseases.

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Download Report: https://www.kuickresearch.com/report-global-car-t-cell-therapy-market-and-clinical-trials-insight-2022.php

Report Table of Contents

1. Chimeric Antigen Receptor (CAR) T Cell Therapy - Next Era in Immuno Oncology
1.1 Overview
1.2 History and Development of CAR-T Technology

2. Evolution of Chimeric Antigen Receptor (CAR) T-Cell Design
2.1 Structure of CAR T Cell
2.2 1nd Generation Chimeric Antigen Receptor
2.3 2nd and 3nd Generation CAR T Cell

3. Principle of Chimeric Antigen Receptor Design
3.1 CAR Modified T Cells: Targeting
3.2 CAR Modified T Cell: Signaling

4. CAR T Cell Therapies Delivery Pipeline and Mechanism of Action
4.1 Process of CAR T Cell Therapy
4.2 Mechanism of Action

5. Approaches to Improve the CAR T Cell Therapy
5.1 Introduction
5.2 Targeting the Tumor Stroma with CAR T Cells
5.3 Targeting the Cytokine Networks
5.4 Combination Strategies for CAR T Cells
5.5 Targeting the Immune Checkpoints

6. Global CAR T Cell Therapy Clinical Trials for Cancer Treatment
6.1 Acute Lymphoblastic Leukemia
6.2 Multiple Myeloma
6.3 Brain Tumors
6.4 Lymphoma
6.5 Solid Tumors

7. Global CAR T Cell Therapies Clinical Pipeline by Company, Indication and Phase
7.1 Research
7.2 Preclinical
7.3 Clinical
7.4 Phase-I
7.5 Phase-I/II
7.6 Phase-II
7.7 Preregistration

8. Global Market Scenario of CAR T Cell Therapy
8.1 Overview
8.2 Estimated Price Analysis of CAR T Cell Therapy

9. Global Market Size of CAR T Cell Therapy
9.1 Market Share of Cancer Immunotherapy by its Technology
9.2 CAR T Cell Therapy Market Value

10. Global CAR T Cell Therapy Market Dynamics
10.1 Favorable Parameters
10.2 Challenges

11. Global CAR T Cell Therapy Market Future Prospects

12. Competitive Landscape
12.1 Autolus
12.2 Bellicum
12.3 Bluebird
12.4 Celgene
12.5 Cellectis
12.6 Celyad
12.7 Eureka Therapeutics
12.8 Fortress Biotech
12.9 Immune Therapeutics
12.10 Juno Therapeutics
12.11 Kite Pharma
12.12 Novartis
12.13 Sorrento therapeutics
12.14 TILT Biotherapeutics
12.15 Ziopharm

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.